Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder Michael P. Bogenschutz, 2022
Randomised double-blind trial of two psilocybin doses plus psychotherapy for alcohol use disorder, reporting heavy drinking days over 32 weeks; clinical outcomes in patients.
Report an error
D2 n/a 2 32 weeks after first dose Abstract Signed by Max Markovtsev, founder
14 November 2026
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Roland R. Griffiths, 2016
Randomized double-blind crossover trial of high versus very low dose psilocybin in 51 cancer patients, reporting depression and anxiety to 6 months.
Report an error
D2 n/a 2 6 months Abstract Signed by Max Markovtsev, founder
14 November 2026
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Martin Korsbak Madsen, 2019
Report an error
D1 During the drug 1 acute (same day) Abstract Screened by AI
Psychedelics Promote Structural and Functional Neural Plasticity Calvin Ly, 2018
Report an error
D3 n/a none not stated Full text Checked by Astra, a second AI model
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Alan K. Davis, 2020
Randomized waiting-list controlled trial of two psilocybin sessions in 27 adults with major depressive disorder, reporting depression at 1 and 4 weeks.
Report an error
D2 n/a 2 1 and 4 weeks Abstract Signed by Max Markovtsev, founder
14 November 2026
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Robin Lester Carhart-Harris, 2012
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors Maxemiliano V. Vargas, 2023
Report an error
D3 n/a none not stated Full text Checked by Astra, a second AI model
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study Robin Lester Carhart-Harris, 2016
Open-label trial of two psilocybin doses in treatment-resistant depression reporting depressive symptoms from one week to three months; a human trial with clinical outcomes.
Report an error
D2 n/a 2 3 months Abstract Signed by Max Markovtsev, founder
14 November 2026
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Stephen Ross, 2016
Randomized placebo-controlled crossover trial of single-dose psilocybin versus niacin in 29 cancer patients, reporting anxiety and depression to 6.5 months.
Report an error
D2 n/a 1 7 weeks; 6.5 months Abstract Signed by Max Markovtsev, founder
14 November 2026
A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain Nakul Ravi Raval, 2021
Report an error
D1 After the acute effects 1 1 day and 7 days Abstract Screened by AI
Emotions and brain function are altered up to one month after a single high dose of psilocybin Frederick Streeter Barrett, 2020
Report an error
D1 After the acute effects 1 1 month Abstract Screened by AI
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience Martin Korsbak Madsen, 2021
Report an error
D1 During the drug 1 acute (up to 5 hours) Abstract Screened by AI
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression Matthew B. Wall, 2025
Report an error
D1 After the acute effects 2 3 weeks Abstract Screened by AI
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up Natalie Gukasyan, 2022
Report an error
D2 n/a 2 12 months Abstract Screened by AI
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice Natalie Hesselgrave, 2021
Report an error
D1 Not yet sorted 1 not stated Abstract Screened by AI
Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals Drummond E-Wen McCulloch, 2021
Report an error
D1 After the acute effects 1 1 week; 3 months Abstract Checked by Astra, a second AI model
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder Manoj K. Doss, 2021
Report an error
D1 After the acute effects not stated 1 week Abstract Screened by AI
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up Robin Lester Carhart-Harris, 2017
Report an error
D2 n/a 2 6 months Abstract Screened by AI
Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression Gustavo Deco, 2024
Report an error
D1 After the acute effects 2 3 weeks after second dose Abstract Screened by AI
Dynamic coupling of whole-brain neuronal and neurotransmitter systems Morten L. Kringelbach, 2020
Report an error
D1 Not yet sorted not stated not stated Abstract Screened by AI
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression Leor Roseman, 2017
Report an error
D1 Not yet sorted 2 1 day Abstract Screened by AI
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob, 2010
Report an error
D2 n/a 1 1, 3 and 6 months Abstract Screened by AI
Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity Débora Copa, 2024
Report an error
D2 n/a 2 up to 24 weeks Abstract Screened by AI
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms Robin Lester Carhart-Harris, 2017
Report an error
D1 Not yet sorted not stated not stated Abstract Screened by AI
Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity Katrin H. Preller, 2020
Report an error
D1 During the drug 1 acute (20 to 70 minutes) Abstract Screened by AI
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin Joshua Daniel Rosenblat, 2024
Report an error
D2 n/a 1, 2 or 3 2 weeks (primary endpoint) Abstract Checked by Astra, a second AI model
Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors Ling-Xiao Shao, 2025
Report an error
D1 During the drug 1 not stated Abstract Screened by AI
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB Rafael Moliner, 2023
Report an error
D3 n/a not stated not stated Abstract Screened by AI
Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study Luca Pellegrini, 2025
Report an error
D2 n/a 2 1 week; 4 weeks Abstract Screened by AI
Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial Robin von Rotz, 2022
Report an error
D2 n/a 1 14 days Abstract Screened by AI
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers Leor Roseman, 2014
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression Lea Julia Mertens, 2020
Report an error
D1 After the acute effects not stated 1 day Abstract Screened by AI
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression Brandon Weiss, 2023
Report an error
D2 n/a not stated not stated Abstract Screened by AI
Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations Michael Kometer, 2013
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice Nicole Fadahunsi, 2022
Report an error
D1 Not yet sorted 1 not stated Abstract Screened by AI
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression Melissa Shukuroglou, 2022
Report an error
D1 Not yet sorted 2 1 day Abstract Screened by AI
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial Emmanuelle A. D. Schindler, 2022
Report an error
D2 n/a 3 3 to 8 weeks after first dose Abstract Screened by AI
High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin Dotan Braun, 2024
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Increased low-frequency brain responses to music after psilocybin therapy for depression Matthew B. Wall, 2023
Report an error
D1 After the acute effects 2 1 day Abstract Screened by AI
Pilot study of psilocybin in patients with post-treatment lyme disease Albert Garcia‐Romeu, 2026
Report an error
D2 n/a 2 1 month after second dose; 6 months Abstract Screened by AI
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity Yingjie Du, 2023
Report an error
D1 Not yet sorted 1 not stated Abstract Screened by AI
Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice Xiangting Zhao, 2024
Report an error
D1 Not yet sorted 1 not stated Abstract Screened by AI
Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function Jonah A. Padawer-Curry, 2025
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin Pasha A. Davoudian, 2023
Report an error
D1 During the drug not stated acute Abstract Screened by AI
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world Rosalind Watts, 2022
Report an error
D2 n/a not stated 6 weeks Abstract Screened by AI
UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice Daniel Ryskamp Rijsketic, 2023
Report an error
D1 During the drug not stated not stated Abstract Screened by AI
A multi-institutional investigation of psilocybin’s effects on mouse behavior Odilia Lu, 2026
Placed from the full text under rule D3: Mechanistic plasticity or critical-period study with a psilocybin or psilocin arm.
Report an error
D3 n/a 1 Acute tests ~10 min after drug administration; persistent tests at least 24 h after drug administration, up to 4 d after drug administration for the corticosterone forced swim test; social reward adults pre-treated 4–5 d before the start of experiments, with the post-test on day 5 Full text Signed by Max Markovtsev, founder
11 November 2026
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression Balázs Szigeti, 2024
Report an error
D2 n/a not stated not stated Abstract Screened by AI
Brain dynamics predictive of response to psilocybin for treatment-resistant depression Jakub Vohryzek, 2024
Report an error
D2 n/a 2 not stated Abstract Screened by AI
Broadband Cortical Desynchronization Underlies the Human Psychedelic State Suresh D Muthukumaraswamy, 2013
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression Farid Aboharb, 2025
Report an error
D1 Not yet sorted not stated not stated Abstract Screened by AI
Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats Evan Fuini, 2025
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin Louis-David Lord, 2019
Report an error
D1 During the drug 1 acute Abstract Screened by AI
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression Tommaso Barba, 2022
Report an error
D2 n/a not stated 6 weeks after treatment start Abstract Screened by AI
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies William Roseby, 2025
Report an error
D2 n/a not stated not stated Abstract Screened by AI
Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress Ines Erkizia-Santamaría, 2025
Report an error
D1 Not yet sorted 2 not stated Abstract Screened by AI
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS) Richard J. Zeifman, 2025
Report an error
D1 During the drug 2 acute Abstract Screened by AI
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer Gabrielle Agin-Liebes, 2020
Report an error
D2 n/a 1 3.2 and 4.5 years Abstract Screened by AI
Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study Sara Ellis, 2025
Report an error
D2 n/a 1 12 months Abstract Screened by AI
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression Brandon Weiss, 2023
Report an error
D2 n/a not stated 6 months Abstract Screened by AI
Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder Franklin R. Schneier, 2023
Report an error
D2 n/a 1 12 weeks Abstract Screened by AI
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial Jacob S. Aday, 2025
Report an error
D2 n/a 2 1 month Abstract Screened by AI
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication Guy M. Goodwin, 2023
Report an error
D2 n/a 1 3 weeks Abstract Screened by AI
Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms Kyna‐Anne Conn, 2024
Report an error
D1 Not yet sorted not stated not stated Abstract Screened by AI
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic Anthony L. Back, 2024
Report an error
D2 n/a 1 28 days Abstract Screened by AI
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial Ellen Bradley, 2025
Report an error
D2 n/a 2 1 month; 3 months Abstract Screened by AI
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial Jordan Sloshower, 2023
Report an error
D2 n/a 1 not-stated (16-week study) Abstract Screened by AI
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial Nathalie M. Rieser, 2025
Report an error
D2 n/a 1 4 weeks and 6 months Abstract Checked by Astra, a second AI model
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Michael P. Bogenschutz, 2015
Report an error
D2 n/a 1 or 2 not stated Abstract Checked by Astra, a second AI model
Psychedelics align brain activity with context Devon Stoliker, 2026
Report an error
D1 During the drug 1 acute (about 80 to 150 minutes) Abstract Screened by AI
Psychedelics and the ‘inner healer’: Myth or mechanism? Joseph M. Peill, 2024
Report an error
D2 n/a 1 not stated Abstract Screened by AI
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Leor Roseman, 2018
Report an error
D2 n/a 2 5 weeks Abstract Screened by AI
Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain’s control energy landscape S. Parker Singleton, 2022
Report an error
D1 During the drug not stated acute Abstract Screened by AI
Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis Aline Frick, 2026
Report an error
D2 n/a not stated not stated Abstract Screened by AI
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life Guy M. Goodwin, 2023
Report an error
D2 n/a 1 3 weeks Abstract Screened by AI
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial Scott T. Aaronson, 2025
Report an error
D2 n/a 1 3 weeks and 12 weeks Abstract Screened by AI
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain Ahmad Hammo, 2025
Report an error
D1 Not yet sorted 1 not stated Abstract Screened by AI
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes Scott T. Aaronson, 2023
Report an error
D2 n/a 1 3 weeks; 12 weeks Abstract Screened by AI
The hidden therapist: evidence for a central role of music in psychedelic therapy Mendel Kaelen, 2018
Report an error
D2 n/a not stated 1 week Abstract Screened by AI
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression Guy M. Goodwin, 2024
Report an error
D2 n/a 1 3 weeks Abstract Screened by AI
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder Adam W. Levin, 2024
Report an error
D2 n/a 2 4 weeks to 12 months Abstract Screened by AI
The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience Hanna M. Tolle, 2023
Report an error
D1 During the drug not stated acute Abstract Screened by AI